Crossmark

Pioglitazone, an anti-diabetic drug requires sustained MAPK activation for its anti-tumor activity in MCF7 breast cancer cells, independent of PPAR-γ pathway

Crossref DOI link: https://doi.org/10.1016/j.pharep.2015.08.001

Published Print: 2016-02

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Kole, Labanyamoy

Sarkar, Mrinmoy

Deb, Anwesha

Giri, Biplab
License Information

Text and Data Mining valid from 2016-02-01
More Information

This article is maintained by: Elsevier

Article Title: Pioglitazone, an anti-diabetic drug requires sustained MAPK activation for its anti-tumor activity in MCF7 breast cancer cells, independent of PPAR-γ pathway

Journal Title: Pharmacological Reports

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.pharep.2015.08.001

Content Type: article

Copyright: Copyright © 2015 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.

Document is current

Any future updates will be listed below